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New Findings 
 
While SGLT2 inhibitors represent a promising treatment for patients suffering from 
diabetic nephropathy, the role of metabolic disruption on the expression and function 
of glucose transporters is largely unknown. 
 
In vivo models of metabolic disruption (Goto-kakizaki type II rat and junk-food diet) 
demonstrate increased expression of SGLT1, SGLT2 and GLUT2 in the proximal 
tubule brush-border.  In the type II model, this is accompanied by increased SGLT- 
and GLUT-mediated glucose uptake. A fasted model of metabolic disruption (high-fat 
diet) demonstrated increased GLUT2 expression only.  The differential alterations in 
glucose transporters in response to varying metabolic stress, offer insight into the 
therapeutic value of inhibitors. 
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Abstract  
 
Objective: SGLT2 inhibitors are now in clinical use to reduce hyperglycemia in type II 
diabetes. However, renal glucose reabsorption across the brush border membrane 
(BBM) is not completely understood in diabetes.  Increased consumption of a 
Western diet is strongly linked to type II diabetes.  This study aimed to investigate 
the adaptations that occur in renal glucose transporters in response to experimental 
models of diet-induced insulin resistance.      
Research Design and Methods: The study used Goto-Kakizaki type II diabetic rats 
and normal rats rendered insulin resistant using junk-food or high-fat (HFD) diets.  
Levels of PKC-βI, GLUT2, SGLT1 and 2 were determined by western blotting of 
purified renal BBM.  GLUT- and SGLT-mediated [3H]-glucose uptake by BBM 
vesicles was measured in the presence and absence of the SGLT inhibitor phlorizin. 
Results: GLUT- and SGLT-mediated glucose transport were elevated in type II 
diabetic rats, accompanied by increased expression of GLUT2, its upstream 
regulator PKC-βI, and SGLT1 protein.  Junk-food and HFD feeding also caused 
higher membrane expression of GLUT2 and its upstream regulator PKC-βI. 
However, the junk-food diet also increased SGLT1 and 2 levels at the proximal 
tubule BBM.  
Conclusions: Glucose reabsorption across the proximal tubule BBM, via GLUT2, 
SGLT1 and 2, is not solely dependent on glycemic status, but is also influenced by 
diet-induced changes in glucose metabolism.  We conclude that different metabolic 
disturbances result in complex adaptation in renal glucose transporter protein levels 
and function. 
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Introduction 
 
Diabetic nephropathy is a major complication of diabetes and a leading cause of 
end-stage renal disease. Chronic hyperglycemia is associated with tubulo-interstitial 
changes that accompany progressive renal dysfunction . While it has been difficult to 
show a clear cardiovascular benefit from tighter glycemic control in diabetes, at least 
in the short-term (Boot-Handford & Heath, 1981; Phillips et al., 1997), available 
evidence favors a long-term reduction in hyperglycemia as an important treatment 
goal in preventing nephropathy (Dluhy & McMahon, 2008; Duckworth et al., 2009). 
Thus, renal glucose reabsorption has been considered to have a pathophysiological 
role in diabetes (Debnam & Unwin, 1996). 
 
In euglycemic conditions, the majority of filtered glucose is reabsorbed by the high-
capacity transporter SGLT2 at the brush border membrane (BBM) of the early 
proximal convoluted tubule, while the remainder is scavenged by the high-affinity 
SGLT1 in the late proximal straight tubule (Turner & Silverman, 1977; Barfuss & 
Schafer, 1981; Cramer et al., 1992; Brown, 2000).  Adaptation of glucose transport 
at the BBM has been documented in diabetes; in particular, the facilitated 
transporter, GLUT2, is readily detectable at the BBM in animals 2-4 weeks after 
induction of type I diabetes (Marks et al., 2003). Indeed, expression of GLUT2 shows 
a positive correlation with blood glucose levels, and it has been proposed that 
increased renal GLUT2 expression at the BBM is mediated by PKC-βI, since levels 
of this signalling molecule also show a positive correlation with both expression of 
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GLUT2 and blood glucose levels (Goestemeyer et al., 2007).  While there are 
conflicting reports of the impact of diabetes on SGLT-mediated transport (Marks et 
al., 2003; Albertoni Borghese et al., 2009), inhibitors of SGLT2 have been 
demonstrated to increase glycosuria and reduce hyperglycemia in type II diabetes 
(Han et al., 2008).  Indeed, Dapagliflozin, Canaglifozin and Empaglifozin, chemical 
inhibitors of this renal-specific glucose transporter, have all been approved for use in 
Europe as insulin-independent treatments for type II diabetes.  However, the glucose 
transporters SGLT1 and GLUT2 also play a role in glucose reabsorption across the 
proximal tubule brush-border (Marks et al., 2003; Hummel et al., 2011), and may 
represent additional targets for the control of hyperglycemia in diabetes.  Consistent 
with this, studies under euglycemic conditions indicate that SGLT1-mediated renal 
glucose transport increases to compensate for SGLT2 knockdown (Rieg et al., 
2014).  Thus, the role of glucose transporters at the proximal tubule BBM in diabetes 
requires further study. 
 
Western diets have changed dramatically over the last 30 years with a significant 
increase in consumption of calorie-dense processed foods. There is a general 
consensus that the rising prevalence of obesity, type II diabetes, and its essential 
prerequisite, insulin resistance, is related to consumption of these processed and 
calorie-dense foods, rich in saturated fat and carbohydrates with a high glycemic 
index (Bayol et al., 2005; Fulgoni, 2008). Diet-induced obesity is a major risk factor 
for development of the metabolic syndrome, a disorder characterized by impaired 
glucose tolerance, hyperuricemia, hypertriglyceridemia, and hypertension, and which 
is considered to be pre-diabetic (Aguilar-Salinas et al., 2005; Junien & Nathanielsz, 
2007; AlSaraj et al., 2009). Increased consumption of saturated and trans-saturated 
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fats and carbohydrates has also been shown to adversely affect glucose metabolism 
and induce insulin resistance (Moeller et al., 2009).  Consumption of artificial 
sweeteners such as sucralose and saccharin, has also increased significantly in 
recent years (Mattes & Popkin, 2009; Yang, 2010).  Interestingly, both experimental 
studies and meta-analyses have linked the consumption of artificial sweeteners with 
the development of glucose intolerance (Pepino et al., 2013; Suez et al., 2014).  
Therefore, the Western diet likely contributes to the development of insulin 
resistance and type II diabetes through disturbances in glucose homeostasis that are 
determined more by its actual composition. 
 
Since the kidneys play a major role in glucose homeostasis, the aim of the present 
study was to characterize glucose transport at the proximal tubule BBM in 
experimental models associated with metabolic disturbance. Models of early type I 
diabetes, type II diabetes, diet-induced obesity and insulin resistance and exposure 
to artificial sweetener were utilized.  Studies on type II diabetes used Goto-Kakizaki 
(GK) rats, an established non-obese model of the condition characterized by glucose 
intolerance and impaired insulin secretion (Goto et al., 1976).  Since type II diabetes 
in man has been attributed to the high consumption of “junk-foods” in the Western 
diet (Hu et al., 2001), an earlier stage in type II diabetes pathogenesis was studied 
using rats maintained either on a cafeteria diet composed of processed foods or a 
defined high-fat diet. Finally, animals acutely exposed to the artificial sweetener 
saccharinwere compared.  Our studies demonstrate a differential expression profile 
of glucose transporters at the BBM in response to these various forms/stages of 
metabolic disease.  We propose that specific glucose transporters could be targeted 
at the proximal tubule BBM to attenuate glucose reabsorption and potentially lessen 
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hyperglycemia in diabetes or pre-diabetes, and may even provide eventual 
renoprotection. 
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Methods  
 
Ethical approval 
All procedures were carried out in accordance with the UK Animals (Scientific 
Procedures) Act, 1986 Amendment Regulations 2012. The protocol was approved 
by the University College London (Royal Free Campus) Comparative Biology Unit 
Animal Welfare and Ethical Review Body (AWERB) committee.   
 
Animal models 
Type I diabetes was induced by a single tail vein injection of streptozotocin (STZ) (55 
mg.kg-1) administered to male Sprague-Dawley rats (200-230 g) 7 days prior to 
experimentation. This protocol was chosen because hyperglycemia of at least 7 day 
duration is required for detection of increased GLUT2 expression at the BBM (data 
not shown). STZ was freshly prepared in 0.05 M citrate buffer and administered 
under light inhaled isofluorane anesthesia (2% isofluorane in 100% oxygen, non-
terminal). Control animals received an injection of citrate buffer. Type II diabetes was 
studied in 8-9 week old non-obese Goto-Kakizaki (GK) rats (Goto et al., 1976) 
purchased from Charles River, USA, and compared to Wistar controls.  
 
Type I and Type II diabetic animals were allowed ad libitum access to a standard rat 
chow (diet RM1, SDS Ltd, Witham, Essex, UK) and water. For ‘junk-food’ (‘cafeteria 
diet’) feeding studies, male Wistar rats were allowed ad libitium access to water and 
either a standard rat maintenance diet (Diet RM3, SDS Ltd) or chow supplemented 
with junk-food over an 8-week period (Rothwell & Stock, 1979; Bayol et al., 2005).  
The junk-food diet consisted of a choice of palatable, processed foods with high fat 
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and/or high sugar content, comprised of potato crisps (5.7% of consumed food), 
flapjacks (12.3% of consumed food), cheese (4.9% of consumed food), 
marshmallows (6.9% of consumed food), muffins (12.1% of consumed food), 
doughnut (19.8% of consumed food), biscuits (31.1% of consumed food) and 
chocolate bars (7.2% of consumed food). Daily energy consumption for chow fed 
and junk-food fed animals was 17.5 kcal (73.2 kJ) and 198 kcal (830.6 kJ), 
respectively. For the high-fat diet model, male Wistar rats (125-150 g) were 
purchased from Charles River (UK) and had ad libitum access to a 60% fat-as-
calories chow (R12492, Research Diets, New Brunswick, USA) over a 5-week period 
or maintenance diet. Rats maintained on a high-fat diet were fasted overnight prior to 
being euthanised by exposure to gradually increasing concentration of carbon 
dioxide.  At the end of the diabetic or junk feeding protocols, unfasted animals were 
terminally anesthetized with an intraperitoneal (i.p.) injection of pentobarbitone 
sodium (60 mg.kg-1) (Pentoject, Animalcare Ltd, York, UK).   Monitoring of the pedal 
and corneal reflex was undertaken to ensure deep anaesthesia was achieved before 
blood was taken by cardiac puncture, and the kidneys removed. Death after 
exsanguination was ensured by incising the heart. Cortical fragments were dissected 
at 4oC and either snap-frozen for BBM preparation for Western blotting studies or 
BBM vesicles were freshly prepared for glucose uptake studies. 
 
Plasma glucose concentration was measured using the glucose oxidase assay 
(Huggett & Nixon, 1957) and plasma insulin was quantified using a sandwich ELISA 
kit (Millipore, UK). 
 
Animal procedures - Infusion studies 
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For infusion experiments, 8-9 week old male Sprague-Dawley rats, allowed ad 
libitum access to RM1 diet containing 65% carbohydrate, were anesthetized with an 
i.p. injection of pentobarbitone sodium (60 mg.kg-1) and the jugular vein and bladder 
were cannulated.  Test animals were infused with 154 mM NaCl at 5.5 ml.h-1 for 1 h, 
followed by 1 mM saccharin in 154 mM NaCl for a further 2 h, while control animals 
continued to receive 154 mM NaCl. At the end of the infusion protocol blood was 
collected by cardiac puncture and the kidneys removed. Cortical fragments were 
dissected at 4oC and BBM vesicles immediately prepared for studies of glucose 
uptake.  
 
Preparation of renal BBM and glucose uptake studies 
 BBM vesicles were prepared from kidney cortex, using a double Mg2+ chelation 
protocol, as described previously (Marks et al., 2003).  Purity of the BBM preparation 
was confirmed by 6-8-fold enrichment of alkaline phosphatase.  Protein 
concentration was determined using a Bradford assay (Bradford, 1976).  Uptake 
studies were carried out as described previously (Marks et al., 2003). In brief, the 
transport process was initiated by mixing equal volumes of vesicle suspension and 
uptake buffer consisting of (mM) 200 NaSCN, 20 Hepes, 0.1 MgSO4 containing D-
[3H]glucose and such that the final concentration of glucose was 30-960 µM to 
determine the transport kinetics of SGLT-mediated glucose transport. Uptake was 
terminated after 4 s by the addition of 3 ml of 154 mM NaCl containing 0.5 
mM phlorizin, followed by vacuum filtration through 0.45 µm nitrocellulose filters 
(Sartorius, Germany). Three further washes were carried out. In order to assess 
GLUT-mediated transport, a higher glucose concentration (20 mM) was used in the 
presence of 1 mM phlorizin - this value is consistent with the low affinity of GLUT 
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transporters for glucose binding (Debnam & Unwin, 1996). The kinetic parameters of 
Vmax (maximum transport capacity) and Kt (glucose concentration at half Vmax) for 
phlorizin-sensitive uptake were derived using Lineweaver-Burk plot analysis of 
uptake date obtained using a glucose concentration in the µM range.. 
 
Western blotting 
Western blotting of BBM was carried out as previously described (Marks J, 2003, 
553, 137) using rabbit polyclonal antibodies raised against SGLT1 (a gift from Prof. 
G. Kellett, University of York, UK), SGLT2 (Santa Cruz Biotechnology, Santa Cruz, 
USA), GLUT2 (AbD Serotec, Kidlington, UK) and PKC-βI (Santa Cruz). Mouse 
monoclonal antibody for β-actin (Abcam, Cambridge, UK) was used as a loading 
control. Blots were visualized with enhanced chemiluminescence on a Fluor-S 
MultiImager system (BioRad, Hertfordshire, UK), and the abundance of each protein 
of interest was calculated relative to actin and expressed as a percentage of the 
control average. 
 
Statistics 
Values are expressed as mean ± S.E.M.; n values represent numbers per treatment 
group (i.e. 1 animal is equivalent to an n value). For each experiment, a comparison 
between metabolic-treatment group was made relative to control group.  Studies 
were performed to ensure that both control and metabolic-treatment group were 
studied in at the same time point. Differences between groups were tested by 
Student’s unpaired t test, with p<0.05 considered significant.  
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Results 
 
Type II diabetes increases SGLT- and GLUT-mediated transport of glucose 
across the BBM 
Long-term type I diabetes increases glucose transport across the proximal tubule 
BBM through enhanced levels of GLUT2 (Marks et al., 2003).  Our first aim was to 
assess the effect of experimental type II diabetes on renal glucose transport.  In 
keeping with previously published observations (Noll et al., 2011), at 8-9 weeks of 
age GK rats weighed significantly less than control Wistar rats and had an increased 
plasma glucose concentration (Table 1) and glycosuria (data not shown), however, 
the increase in plasma insulin levels in GK rats did not reach significance (Table 1). 
 
BBM vesicles isolated from the kidneys of Wistar control rats were enriched in 
alkaline phosphatase (6.26 ± 1.04-fold, n = 6) and type II diabetes had no significant 
effect on these values (6.26 ± 0.68-fold, n = 6). As previously reported, glucose 
uptake studies revealed the expected time dependent overshoot, which was blocked 
by phlorizin (data not shown) (Marks et al., 2003). Vesicle-trapped space, as 
determined by incubation of BBM vesicles with 100 mM 3H glucose for 15 min, was 
unaffected by type II diabetes (control: 2.84 ± 0.66 vs. GK: 3.60 ± 0.64 µl/mg protein, 
n = 6).  At increasing concentrations of glucose, uptake across the BBM was 
significantly higher in GK rats compared with control animals (Figure 1a).  The Vmax 
for SGLT-mediated glucose uptake was 66% greater in BBM prepared from kidneys 
from type II diabetic rats (control: 1426.1 ± 66.3 vs. GK: 2364.6 ± 433.2 pmol.mg 
protein-1, n = 6-8, P<0.05) and Kt increased by 80% (control: 147.1 ± 21.6 vs. GK: 
264.3 ± 46.1 µM, n = 6-8, P<0.05).  Phlorizin-insensitive, GLUT-mediated glucose 
14 
 
transport, measured at 20 mM, was 130% greater in BBM prepared from Type II 
diabetic animals (Figure 1b).  
 
Western blotting revealed higher levels of GLUT2, SGLT1, and PKC-βI in BBM 
vesicles prepared from GK rats (Figure 2a).  As previously demonstrated (Marks et 
al., 2003; Goestemeyer et al., 2007), exposure to streptozotocin induced 
hyperglycaemia (Table 1).  Interestingly, while GLUT2 and PKC-βI expression at the 
BBM was significantly increased, SGLT1 and SGLT2 levels were unaffected one 
week after STZ injection (Figure 2b).  Therefore our data demonstrate that renal 
glucose transport by SGLT1 and GLUT2 is upregulated at the BBM in a non-obese, 
hyperglycemic model of type II diabetes, but that there are differences in the 
adaptation of renal glucose transport induced in models of type I and type II 
diabetes.  
 
Differential expression profile of glucose transporters at the renal BBM in 
rodent models of diet-induced obesity and insulin resistance 
We next sought to examine whether diet-induced models of obesity and insulin 
resistance affect glucose transporter expression at the renal BBM using two well-
characterized models of diet-induced obesity (Bayol et al., 2005; Anderson et al., 
2009).  Both cafeteria diet and high-fat diet fed rats gained significantly more body 
weight and displayed elevated plasma glucose and insulin levels versus their chow-
fed control groups (Table 1).  Western blotting of BBM prepared from rats maintained 
on both the junk-food and high-fat diet revealed significantly higher GLUT2 levels 
compared with chow fed animals, which was accompanied by increased levels of 
PKC-βI (Figure 2c and d, respectively).  Interestingly, BBM protein levels of SGLT1 
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and 2 was significantly increased in animals fed the junk-food, but not high-fat, diet 
(Figure 1c and d, respectively).  These data demonstrate that expression of glucose 
transporters at the proximal tubule BBM is dependent on the model of diet-induced 
obesity used and is not solely regulated by glycemia or insulinemia. 
 
The artificial sweetener saccharin regulates SGLT-mediated glucose transport 
at the renal BBM 
Activation of sweet taste receptors, localized to the small intestine, have been 
proposed to regulate intestinal glucose transporter expression via activation of sweet 
taste receptors (Mace et al., 2007; Mace et al., 2009). Given the similarity in renal 
glucose handling in the intestine and kidney we wanted to establish whether short-
term i.v. infusion of the artificial sweetener, saccharin, influenced renal glucose 
transport. A 2 hour infusion of 1 mM saccharin had no effect on plasma glucose 
concentration (Table 1). As expected, BBM vesicles isolated from the kidneys of 
saline-infused rats and saccharin-infused rats were enriched in alkaline phosphatase 
(6.81 ± 0.61-fold, n = 6 and 6.64 ± 0.57-fold, n = 6 respectively) and vesicle-trapped 
space was also unaffected by saccharin (in µl/mg protein), saline: 1.49 ± 0.24 vs. 
saccharin: 1.44 ± 0.21, n = 6).  The Vmax for SGLT-mediated glucose uptake was 
143% greater in the renal BBM of saccharin infused rats (control: 959.4 ± 90.5 vs. 
saccharin: 2333 ± 447 pmole.mg protein-1, n = 5, P<0.05), whilst the Kt was 
unaffected (control: 947.4 ± 120.9 vs. saccharin: 1282.4 ± 329 µM, n = 5) (Figure 
3a).  Western blotting revealed that SGLT1, but not SGLT2, expression was 
significantly increased at the proximal tubule BBM (Figure 4).   Renal GLUT-
mediated glucose transport, measured using 20 mM glucose, was unaffected by 
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saccharin infusion (Figure 3b) and in keeping with this finding, protein levels of 
GLUT2 and its upstream regulator PKC-βI were also unchanged (Figure 4). 
 
To establish whether sweet taste receptors might mediate the effect of saccharin on 
SGLT1-dependent glucose transport, we next studied the mRNA expression of 
sweet taste receptors in the rat kidney.  Using RNA from rat small intestine as a 
positive control, qPCR revealed that T1R2, T1R3 and their downstream G-protein, 
alpha-gustducin, were not expressed in the rat kidney (data not shown). This finding 
is in keeping with RNA-seq data published by Lee et al, who, using microdissected 
tubular segments, were unable to demonstrate expression of these receptors in any 
part of the mouse kidney (Lee et al., 2015b). In conflict with this RNA data, the 
antibodies used by Mace et al (Mace et al., 2007; Mace et al., 2009) to investigate 
the effect of saccharin on intestinal taste receptor expression (purchased from Santa 
Cruz Biotechnology) were able to detect a strong signal in renal BBM vesicles. 
However the use of these antibodies in immunohistochemistry demonstrated that 
there was a high degree of non-specific binding, with no particular region of the 
kidney showing positive staining. Taken together our findings suggest a role for 
saccharin in enhancing renal BBM glucose transport through SGLT1, which unlike in 
the small intestine, appears to be independent of the sweet taste receptor T1R2/3. 
 
Discussion 
Diabetic nephropathy is an important late complication of diabetes, especially 
when glycaemic status has been poorly controlled. The use of SGLT2 inhibitors is 
a new treatment modality for maintaining glycemic control in patients with type II 
diabetes, and although it has been suggested that this approach may also limit the 
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long-term renal consequences of diabetic nephropathy, to date it has not been 
shown to provide unequivocal ‘renoprotection’ other than by improving blood sugar 
control. Lack of more direct renoprotection might be a consequence of adaptation 
in glucose transport mechanisms in response to SGLT2 inhibition. For example it 
is known that in healthy volunteers inhibiting SGLT2 reduces reabsorption of 
filtered glucose by only ~ 30–50% (Liu et al., 2012), which may be due to 
scavenging of the abnormally high glucose levels reaching the late proximal tubule 
by SGLT1 (Brown, 2000; Wright, 2001). However, this explanation is largely based 
on studies in non-diabetic mice and does not take account of the potential for 
additional adaptive changes in renal glucose transport that may occur in diabetes. 
In this context, it has also been shown by Vallon et al that although SGLT2 gene 
knockout reduces glycemia in experimental type I diabetes, lack of SGLT2 did not 
abrogate the effects of diabetes on renal growth or markers of renal injury, 
inflammation and fibrosis (Vallon et al., 2013); others have made similar findings 
for SGLT2 inhibition (O'Neill et al., 2015). Thus, understanding how glucose is 
transported across the renal BBM and how the process is upregulated in diabetes 
and pre-diabetes may offer new insights for reducing potential damaging effects of 
increased glucose load and transport on tubular function.  
 
The present study used animal models of diabetes and models of diet-induced 
obesity and insulin resistance of differing aetiology to assess the effects of insulin 
resistance and hyperglycaemia on expression of glucose transporters at the renal 
BBM. Our previous findings have shown that expression of GLUT2 and its regulator, 
PKC-βI, are increased in a model of established type I diabetes (Marks et al., 2003), 
and that their expression levels correlate with changes in glucose concentration 
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within the pathophysiological range (Goestemeyer et al., 2007). In keeping with 
these findings, we have demonstrated that expression of GLUT2 and PKC-βI at the 
renal BBM is higher in type II diabetes and after one week induction of type I 
diabetes. However, we also show increased levels of both GLUT2 and PKC-βI at the 
BBM in animals maintained on junk-food and high-fat diets, even though these 
animals demonstrated only mild elevations in plasma glucose.  The high renal 
GLUT2 expression in the absence of a pronounced glycemic stimulus suggests that 
increased glucose uptake across the BBM can occur in models of insulin resistance 
and impaired glucose tolerance (pre-diabetes), a state known to precede the onset 
of type II diabetes.   
 
Also in agreement with our previous studies using long-term type 1 diabetic rats 
(Marks et al., 2003), we observed no alteration in SGLT1 or SGLT2 expression at 
the renal BBM in response to recent induction of type I diabetes.  However, in the 
GK model of type II diabetes, the capacity for SGLT-mediated glucose transport was 
augmented and this was accompanied by a rise in the level of SGLT1, but not 
SGLT2, protein. Studies using exfoliated proximal tubular epithelial cells obtained 
from the urine of type 2 diabetic patients also show increased SGLT-mediated 
glucose transport, but this was attributed to an increase in SGLT2 activity as a result 
of enhanced mRNA and protein levels (Rahmoune et al., 2005). In addition, some 
studies in genetic mouse models of both type I (Akita mice) and type II (db/db mice) 
diabetes also report increased renal SGLT2 expression and SGLT activity 
respectively (Arakawa et al., 2001; Vallon et al., 2013).  However, it is important to 
note that numerous studies over the past 30 years have provided conflicting results 
on diabetes-induced changes in sodium-dependent glucose transport, and SGLT 
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transporter expression (Debnam & Unwin, 1996; Poulsen et al., 2015), with 
discrepancies being attributed to the dose of STZ used to induce type I diabetes, the 
use of chemical vs genetic models of diabetes, and the severity of the model being 
studied. The complexity of these changes in renal glucose transporter expression is 
also highlighted by the differing transporter expression profiles observed in our junk-
food and high-fat feed models. As with GLUT2, renal SGLT1 and SGLT2 expression 
does not follow a clear pattern with respect to plasma glucose concentrations or 
levels of insulin.  Furthermore, the differential effects of a junk-food or high-fat diet on 
expression of SGLTs and GLUT2 suggest that these transporters are not regulated 
by the same factor(s) in these different dietary models.  
 
At present the identity of this factor(s) is unknown; however, given the similarity 
between the process of glucose transport across enterocytes and renal tubular cells, 
parallels can be drawn over regulation of glucose transport and the possibility of 
glucose ‘sensing’ by the kidney. Sweet taste receptors are transmembrane G-protein-
coupled receptors formed by heterodimerisation of T1R2 and T1R3; this heterodimer 
is sensitive to a variety of different sweet taste molecules including sugars, artificial 
sweeteners and sweet proteins (Li et al., 2002).  Recent studies suggest that 
activation of sweet taste receptors in intestinal epithelium enhances both SGLT1 
expression and GLUT2 insertion into the BBM during carbohydrate digestion (Mace et 
al., 2007; Mace et al., 2009).  Intestinal sweet taste receptor activation by artificial 
sweeteners regulates glucose-dependent GLP1 secretion from L cells, but not GIP 
secretion from K cells (Jang et al., 2007; Parker et al., 2009).  Interestingly, although 
our studies demonstrate that the artificial sweetener saccharin enhances renal SGLT-
mediated glucose transport and SGLT1 protein expression, we were unable to detect 
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T1R2, T1R3 and the downstream signalling protein alpha-gustducin in the kidney by 
qPCR. While numerous sensory receptors have been reported to be expressed in the 
kidney (including taste receptors) (Rajkumar et al., 2014), recent RNAseq data using 
microdissected tubular segments was unable to demonstrate expression of these 
sweet taste receptors in any part of the mouse kidney (Lee et al., 2015b).  Thus it is 
unlikely that the proximal tubule response to saccharin results from ‘classical’ sweet 
taste sensing. 
 
An alternative glucose sensor, SGLT3, is expressed in the submucosal and myenteric 
plexuses of the small intestine (Diez-Sampedro et al., 2003) and duodenal 
enterochromaffin cells (Lee et al., 2015a). Recent studies have shown that SGLT3 is 
involved in the coordinated modulation of glucose absorption (via an increase in distal 
jejunal SGLT1 expression) and GLP-1 secretion (Lee et al., 2015a; Pal et al., 2015), 
with these effects occurring via a vagally-mediated pathway (Pal et al., 2015). 
However, although SGLT3 may play a significant role in glucose sensing in the 
intestine, it is unlikely to be responsible for the increased renal SGLT1 activity in 
response to artificial sweeteners, since, compared with intestinal SGLT3 expression, 
renal levels of SGLT3 mRNA are extremely low (Barcelona et al., 2012) or 
undetectable (Matus Sotak, personal communication).  
 
A potential mechanism through which glucose transporter expression is regulated at 
the proximal tubule BBM is through the local action of insulin.  The insulin receptor is 
present throughout the nephron, including in the proximal tubule, with higher 
expression at the basolateral membrane than at the BBM (Feraille et al., 1995).  The 
action of SGLT2 inhibitors on renal glucose handling is notably independent on insulin 
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action, but this is not the case for GLUT2 activity.  Lowered circulating level of insulin 
in type I diabetes might provide a stimulus for recruitment of GLUT2 to the BBM, an 
action of the hormone that has been noted in jejunal enterocytes (Tobin et al., 2008), 
but would not explain the raised GLUT2 levels at the BBM in the prediabetic state 
seen following feeding of junk-food or high-fat diet.  Therefore, GLUT2 expression at 
the renal BBM, like SGLT expression, is likely to be mediated through an insulin–
independent pathway in metabolic conditions.   
 
The composition of diets has been demonstrated to play a role in glucose transporter 
expression in the small intestine. Consumption of a high-starch/low-fat pellet diet, by 
rats, increases jejunal gene expression of SGLT1 and GLUT2 compared with a low-
starch/high-fat diet, and is likely to increase glucose transport across the intestinal 
brush-border (Inoue et al., 2015).  Interestingly, obese subjects who consume a high-
fat/low-carbohydrate diet display increased brush-border GLUT2 expression under 
fasting conditions (Ait-Omar et al., 2011).  Studies by Gai et al demonstrate that 2441 
genes are differentially expressed in renal tissue following chronic high-fat diet (Gai et 
al., 2014), however no studies focused on renal glucose transporter expression.  Our 
findings show that consumption of a high-fat diet chow elevates GLUT2 expression, 
whereas a diet high in fat and sugars (junk-food diet) increases SGLT1, SGLT2 and 
GLUT2.  It is possible that specific components of the diet, and the ratio of 
carbohydrate to fat, can play a role in renal glucose transporter expression to regulate 
glucose reabsorption.  
 
In conclusion, metabolic dysregulation associated with diabetes evokes changes in 
sodium-dependent and sodium–independent glucose transport across the renal BBM 
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that have the potential to worsen hyperglycaemia or cause diabetic renal injury.  
Although clearly SGLT2 plays a key role in glucose transport across the proximal 
tubule BBM, our data show that the kidney displays differential responses in glucose 
transporter expression depending on the severity and type of metabolic dysfunction 
present. These findings demonstrate the complexity of the adaptive response in renal 
tubular glucose transport in pre-diabetic syndromes and type II diabetes. Furthermore, 
the efficacy of the anti-hyperglycemic effect of SGLT2 inhibitors may vary with the 
progression of disease.  Further characterisation of the signalling pathways involved 
in renal glucose handling may allow a deeper understanding of the effect of SGLT2 
inhibitors in patients with type II diabetes and promote the development of further new 
therapies for the treatment of diabetes and associated kidney disease. 
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Table 1.  Body weight, plasma glucose and insulin levels in models of insulin 
resistance and diabetes.  Results are expressed as mean ± SEM, n=6-12. 
*P<0.05, **P<0.01, ***P<0.005, ****P<0.001 compared with the corresponding 
control rats. nd = not determined. #animals were fasted overnight before samples 
taken. n=6-8 for each disease model.  
 
  
 
Treatment 
group 
Body weight 
(g) 
Plasma glucose 
(mM) 
Plasma 
insulin 
(ng.ml-1) 
Artificial 
sweetener 
study 
Saline 397.7 ± 11.8 5.39 ± 0.2 nd 
Saccharin 409.7 ± 15.3 6.27 ± 0.8 nd 
     
Type I 
diabetes 
study 
Vehicle 268.5 ± 11.3 10.3 ± 0.9 nd 
Streptozotocin 244.4 ± 7.1 35.7 ± 3.4 **** nd 
     
Type II 
diabetes 
study 
Wistar rat 397 ± 7.4 13.3 ± 0.4 4.83 ± 1.12 
Goto-kakizaki 
rat 
316.6 ± 5.2**** 20.3 ± 1.3 **** 6.35 ± 1.38 
     
Diet-induced 
obesity 
study 
Control diet 367.7 ± 15.3 8.5 ± 0.30 2.15 ± 1.09 
Junk-food diet 429 ± 12.4*** 10.7 ± 0.4 *** 9.18 ± 1.51 ** 
    
Control diet# 392.8 ± 4.2 4.2 ± 0.1 4.91 ± 0.87 
High-fat diet# 417.6 ± 9.5* 4.7 ± 0.2 * 10.07 ± 1.76 * 
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Figure legends 
Figure 1 – Effect of type II diabetes on sodium-dependent and independent 
glucose transport across the proximal tubule BBM.  (a) Sodium-dependent 
glucose uptake across the BBM from control Wistar (solid line) and Goto-Kakizaki 
(dashed line) rats at different concentrations of glucose from 29.7 to 957 µM.  (b) 
Sodium-independent glucose transport was measured with or without phlorizin at 20 
mM glucose concentration.  Values are given as mean ± SEM. n=6, *p<0.05, 
***P<0.005 compared to saline infused controls. 
 
 
Figure 2 – Effects of diabetes and diet-induced metabolic disruption on 
expression of SGLT1, SGLT2, GLUT2 and PKC-βI at the proximal tubule BBM.  
Western blotting was performed on proximal tubule BBM from rats under control 
conditions or differing models of metabolic disruption; (a) Type II diabetes, (b) Type I 
diabetes, (c) junk-food diet and (d) high-fat diet. Representative blots (top panel) and 
protein levels of transporters (lower panel) are shown.  Band intensities for each 
transporter are normalised to those of β-actin, expressed as a percentage of the 
control average and are given as mean ± SEM, n=6-8. *P<0.05, **P<0.01, 
***P<0.005, ****P<0.001 compared to control animals.    
 
Figure 3 – Effect of saccharin infusion on sodium-dependent and independent 
glucose transport across the proximal tubule BBM.  (a) Sodium-dependent 
glucose uptake across the BBM from rats exposed to i.v. infusion of saline (solid line) 
and saccharin (dashed line) using concentrations of glucose from 29.7 to 957 µM.  
(b) Sodium-independent glucose transport was measured in the presence and 
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absence of phlorizin at 20 mM glucose concentration. Values are given as mean ± 
SEM. n=5, *p<0.05, ***P<0.005 compared to saline infused controls. 
 
 
Figure 4 – Effect of saccharin infusion on expression of SGLT1, SGLT2, GLUT2 
and PKC-βI at the proximal tubule BBM.  Western blotting was performed on 
proximal tubule BBM from rats exposed to i.v. infusion of saline (open bar) or 
saccharin (closed bar).  Representative blots are shown (top panel) and protein 
levels of transporters (lower panel) are shown. Band densities for each transporter 
are normalised relative to β-actin, expressed as a percentage of the control average 
and given as mean ± SEM, n=6-8. *P<0.05, ***P<0.005 compared to control animals.    
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Supplementary Figure 1 - Representative Western blots performed on proximal 
tubule BBM from rats under control conditions or differing models of metabolic 
disruption. 
Supplementary Figure 2 - Representative Western blots performed on proximal 
tubule BBM from rats exposed to i.v. infusion of saline or saccharin.  
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